Physician profile
Sarah S Elsayed
NPI 1396049029
$12,072.36
in general payments reported to CMS, 2019-2025
39 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,088 · 2020: $894 · 2021: $1,585 · 2022: $1,405 · 2023: $2,207 · 2024: $1,901 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,099.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,900.77 | 2019-2025 | Lifevest |
| Pfizer INC. | $1,142.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,028.37 | 2019-2025 | |
| Penumbra, INC. | $1,002.03 | 2019 | |
| Inari Medical, INC. | $963.32 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.24 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $501.79 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $448.37 | 2020-2025 | Amplatzer Talisman, Confirm Rx, Amplatzer Amulet |
| Janssen Pharmaceuticals, INC | $441.42 | 2019-2023 | Xarelto |
| Medtronic, INC. | $439.48 | 2021-2025 | Symplicity G3, Linq II, Attain Command + Surevalve |
| Biotronik INC. | $438.00 | 2021-2024 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| Sanofi-Aventis U.S. LLC | $432.73 | 2019-2024 | |
| Atricure, INC. | $312.12 | 2019-2025 | Atriclip Laa Exclusion System |
| Alnylam Pharmaceuticals INC. | $306.68 | 2022-2025 | Amvuttra |
| Novo Nordisk INC | $224.24 | 2024-2025 | Wegovy, Ozempic |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $222.94 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $216.10 | 2019-2024 | Farxiga |
| Kestra Medical Technology Services, INC. | $157.16 | 2022-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $145.29 | 2022-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $127.30 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $118.55 | 2019-2022 | |
| Amgen INC. | $112.28 | 2019-2024 | Repatha |
| Janssen Scientific Affairs, LLC | $111.06 | 2021 | |
| Abiomed | $91.12 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $86.11 | 2020-2025 | Evkeeza |
| Merck Sharp & Dohme LLC | $71.71 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $67.60 | 2021 | |
| Heartflow, INC. | $39.05 | 2025 | |
| Lundbeck LLC | $34.16 | 2019 | |
| Edwards Lifesciences Corporation | $34.06 | 2019 | |
| Cardiva Medical, INC. | $30.86 | 2022-2023 | Cardiva Vascade 6/7f Vcs |
| Actelion Pharmaceuticals US, INC. | $28.03 | 2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $23.98 | 2025 | |
| Altathera Pharmaceuticals LLC | $20.68 | 2025 | Sotalol Hydrochloride |
| Gilead Sciences, INC. | $19.92 | 2019 | |
| W. L. Gore & Associates, INC. | $18.47 | 2022 | |
| Zoll Respicardia, INC. | $14.20 | 2025 | Remede System |
| Bayer Healthcare Pharmaceuticals INC. | $14.19 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Elsayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.